DPP-4抑制剂沙格列汀对糖尿病非酒精性脂肪肝的作用研究

发布时间：2018-03-05 04:02

本文选题：沙格列汀　切入点：糖尿病　出处：《重庆医学》2017年11期 　论文类型：期刊论文

【摘要】：目的观察二肽基肽酶4(DPP-4)抑制剂沙格列汀对2型糖尿病合并非酒精性脂肪肝(NAFLD)的作用及疗效。方法40例初发2型糖尿病合并NAFLD患者分为沙格列汀组和二甲双胍组,每组20例。在饮食和运动治疗基础上,沙格列汀组给予每天0.005g沙格列汀,二甲双胍组给予每天0.85~1.70g二甲双胍。观察两组患者治疗前和治疗后3个月的糖化血红蛋白(HbA1c)、三酰甘油(TG)、血压(BP)、丙氨酸氨基转移酶(ALT)、肝脏CT值及肝脏/脾脏CT比值。结果治疗后3个月,两组的TG、ALT、肝脏CT值及肝脏/脾脏CT比值较治疗前差异有统计学意义(P0.05),两组比较差异无统计学意义(P0.05)。结论在糖尿病合并NAFLD的状态下,沙格列汀对减轻脂肪肝有一定的作用。
[Abstract]:Objective to observe the effects of salgletine, a dipeptidyl peptidase 4DPP-4) inhibitor, on type 2 diabetes mellitus with nonalcoholic fatty liver. Methods 40 patients with primary type 2 diabetes complicated with NAFLD were divided into two groups: salgletine group and metformin group. On the basis of diet and exercise therapy, the salgletine group was given 0.005g of salgletine daily. The patients in metformin group were given 0.85 卤1.70 g metformin per day. The HbA1cU, TGG, BP, alt, CT value of liver and CT ratio of liver to spleen were observed before and 3 months after treatment. Results 3 months after treatment, The difference of liver CT value and liver / spleen CT ratio between the two groups was statistically significant compared with that before treatment (P 0.05), but there was no significant difference between the two groups (P 0.05). Conclusion in the condition of diabetes mellitus complicated with NAFLD, salgletine has a certain effect on alleviating fatty liver.
【作者单位】：重庆市人民医院(中山院区)内分泌科;
【基金】：重庆市卫生局医学科研项目(2012-2-189)
【分类号】：R587.1;R575.5

【相似文献】